Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

by Sheelagh Frame, Chiara Saladino, Craig MacKay, Butrus Atrash, Peter Sheldrake, Edward McDonald, Paul A Clarke, Paul Workman, David Blake, Daniella Zheleva
Published 2020-01-01